Salarius Pharmaceuticals, Inc.
Salarius Pharmaceuticals is a clinical-stage biopharmaceutical company developing cancer therapies. They focus on correcting dysregulated gene expression in cancer cells using targeted protein inhibitors (TPIs) and targeted protein degraders (TPDs). Their lead protein inhibitor, seclidemstat (SP-2577), is in phase 1/2 trials for Ewing sarcoma and hematologic cancers. The company has received support from CPRIT and the National Pediatric Cancer Foundation. SP-3164 is expected to enter the clinic in the second half of 2023.
Officielt Register
AI Kvalitetsanalyse
Tillidsscore Detaljer
Genveje
Hjemmeside Højdepunkter
🌟 Lignende Troværdige Virksomheder
UroGen Pharma Ltd.
UroGen Pharma is a biopharmaceutical company focused on developing and commercializing innovative treatments for urologic cancers. They utilize RTGel® technology for sustained local delivery of medications to the urinary tract. Their key products include Jelmyto® and Zusduri™, representing advancements in uro-oncology treatment.
INCYTE CORP
Incyte is a global biopharmaceutical company focused on discovering, developing, and commercializing innovative therapies. They specialize in oncology and dermatology. The company is committed to improving patient outcomes through scientific excellence and a passion for innovation.
SOLENO THERAPEUTICS INC
Soleno Therapeutics is a biopharmaceutical company focused on developing and commercializing novel therapeutics for rare diseases. They are committed to improving the lives of individuals with complex, life-threatening rare diseases. The company aims to maximize shareholder value through innovative therapeutic products.